[go: up one dir, main page]

MX2019000566A - Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. - Google Patents

Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.

Info

Publication number
MX2019000566A
MX2019000566A MX2019000566A MX2019000566A MX2019000566A MX 2019000566 A MX2019000566 A MX 2019000566A MX 2019000566 A MX2019000566 A MX 2019000566A MX 2019000566 A MX2019000566 A MX 2019000566A MX 2019000566 A MX2019000566 A MX 2019000566A
Authority
MX
Mexico
Prior art keywords
small molecule
binding protein
mediated delivery
molecule conjugates
evs
Prior art date
Application number
MX2019000566A
Other languages
English (en)
Inventor
Wiklander Óscar
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of MX2019000566A publication Critical patent/MX2019000566A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

La presente invencion se relaciona a vesiculas extracelulares (VEs) que comprenden una proteina de enlace que puede usarse para el suministro de conjugados de proteina-farmaco que comprenden la proteina de enlace y un agente de molecula pequena, normalmente un farmaco de molecula pequena. La presente invencion tambien se relaciona con metodos para producir dichas VEs asi como composiciones farmaceuticas y usos medicos de dichas VEs.
MX2019000566A 2016-07-12 2017-07-11 Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. MX2019000566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1612110.5A GB2552774A (en) 2016-07-12 2016-07-12 EV-Mediated delivery of binding protein-small molecule conjugates
PCT/EP2017/067372 WO2018011191A1 (en) 2016-07-12 2017-07-11 Ev-mediated delivery of binding protein-small molecule conjugates

Publications (1)

Publication Number Publication Date
MX2019000566A true MX2019000566A (es) 2019-06-10

Family

ID=56890808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000566A MX2019000566A (es) 2016-07-12 2017-07-11 Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.

Country Status (12)

Country Link
US (1) US20190290585A1 (es)
EP (1) EP3484522A1 (es)
JP (1) JP7197464B2 (es)
KR (1) KR20190031259A (es)
CN (1) CN109689109A (es)
AU (1) AU2017297728A1 (es)
BR (1) BR112019000528A2 (es)
CA (1) CA3030366A1 (es)
GB (1) GB2552774A (es)
MX (1) MX2019000566A (es)
SG (1) SG11201811150WA (es)
WO (1) WO2018011191A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019197442A1 (en) * 2018-04-12 2019-10-17 Unicyte Ev Ag A combination of active ingredients for the treatment of tumor
GB201809622D0 (en) * 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
CN108753822A (zh) * 2018-06-20 2018-11-06 中国人民解放军第四军医大学 递送融合型rna结合蛋白的表达载体及其制备方法和应用
CN108753806A (zh) * 2018-06-20 2018-11-06 中国人民解放军第四军医大学 增强目标rna装载入外泌体的融合蛋白的表达载体及其构建方法和应用
KR20210045409A (ko) * 2018-08-14 2021-04-26 에버사이트 게엠베하 표적 특이적 세포외 소포
CN109234237B (zh) * 2018-09-30 2020-08-07 中国人民解放军第四军医大学 一种装载ABCA1 mRNA的外泌体及其构建方法和应用
CN109295081B (zh) * 2018-10-17 2020-06-12 中国人民解放军第四军医大学 一种LDLR-Lamp2b融合基因、表达载体及其应用
CN113286826A (zh) * 2018-10-19 2021-08-20 俄亥俄州国家创新基金会 用于针对髓源性抑制细胞的靶向治疗的细胞外囊泡
EP3921432A1 (en) * 2019-02-04 2021-12-15 Codiak BioSciences, Inc. Membrane protein scaffolds for exosome engineering
MX2021011242A (es) * 2019-03-21 2022-01-19 Codiak Biosciences Inc Conjugados de vesícula extracelular y usos de estos.
WO2020204161A1 (ja) * 2019-04-04 2020-10-08 日産化学株式会社 細胞外小胞の分泌を促進するための組成物
BR112022002599A2 (pt) * 2019-08-14 2022-07-19 Codiak Biosciences Inc Vesícula extracelular ligada a moléculas e usos da mesma
US20230132093A1 (en) * 2019-08-14 2023-04-27 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
CN111333653A (zh) * 2019-12-16 2020-06-26 山东大学 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
CN115209956A (zh) * 2020-02-28 2022-10-18 国立大学法人金泽大学 抗原呈递细胞外囊泡、含有其的组合物及用于制造它们的方法
CN111905105B (zh) * 2020-07-02 2023-05-05 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
GB202015399D0 (en) * 2020-09-29 2020-11-11 Evox Therapeutics Ltd Engineered extracellular vesicles displaying enhanced pharmacokinetics
CN113648430B (zh) * 2021-06-17 2023-03-28 四川大学华西医院 负载药物的dna折纸筏及其制备方法、应用
WO2023284380A1 (zh) * 2021-07-15 2023-01-19 呈诺再生医学科技(北京)有限公司 细胞作为基因治疗的载体在临床中的应用
JP2023104650A (ja) * 2022-01-18 2023-07-28 ダイセン・メンブレン・システムズ株式会社 細胞外小胞の分離精製方法
CN114452266B (zh) * 2022-02-09 2023-05-19 南京凯玛生物科技有限公司 一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用
CN114606251B (zh) * 2022-03-30 2023-02-28 呈诺再生医学科技(珠海横琴新区)有限公司 以外泌体为载体的dna递送系统
WO2024000263A1 (en) * 2022-06-29 2024-01-04 Beijing Thera Bioscience Co., Ltd. Methods for manufacturing and using extracellular vesicles
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
WO2025068572A2 (en) 2023-09-29 2025-04-03 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
KR20020020730A (ko) * 1999-06-09 2002-03-15 오트리브 데이비스 더블유 Ｂ-세포를 표적하는 항체를 이용한 자가면역질환의 면역치료
US20050036984A1 (en) * 2003-06-17 2005-02-17 Harrison Roger G. Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
US20100047334A1 (en) * 2006-10-06 2010-02-25 Sofou Stavroula Ph sensitive liposome compositions for controlling surface topography and binding reactivity in functionalized liposomes
WO2012087241A1 (en) * 2010-12-20 2012-06-28 Agency For Science, Technology And Research Method of purifying exosomes
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
US20150297639A1 (en) * 2012-04-18 2015-10-22 Rhode Island Hospital, A Lifespan-Partner Treating cancer
EP3335721A1 (en) 2013-04-12 2018-06-20 Evox Therapeutics Limited Therapeutic delivery vesicles
US20160346334A1 (en) * 2014-02-05 2016-12-01 Stc.Unm Exosomes as a therapeutic for cancer
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
KR20190031259A (ko) 2019-03-25
JP2019521140A (ja) 2019-07-25
AU2017297728A1 (en) 2019-02-07
WO2018011191A1 (en) 2018-01-18
JP7197464B2 (ja) 2022-12-27
EP3484522A1 (en) 2019-05-22
BR112019000528A2 (pt) 2019-04-24
CA3030366A1 (en) 2018-01-18
GB2552774A (en) 2018-02-14
SG11201811150WA (en) 2019-01-30
CN109689109A (zh) 2019-04-26
US20190290585A1 (en) 2019-09-26
GB201612110D0 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
MX2019007144A (es) Nuevos agonistas de tnfr y sus usos.
MX2018014509A (es) Exosomas que contienen polipeptidos terapeuticos.
WO2014168548A8 (en) Therapeutic delivery vesicles
NZ710729A (en) Amatoxin derivatives
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
NZ701573A (en) Carriers for improved drug delivery
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2015004362A (es) Derivados de ketamina.
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
EP4331622A3 (en) Integrin binding peptides and uses thereof
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
UA117154C2 (uk) Антагоністи s1p3
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
BR112015023233A2 (pt) conjugados de hemoglobina, composição farmacêutica e métodos de tratamento
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
WO2021054927A3 (en) Glutathione-cholesterol derivatives as brain targeting agents
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof